Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 studyCarlo Visco, Monica Balzarotti, Maria Chiara Tisi et al.|The Lancet Haematology|2025Cited by 6
DNA mismatch repair defect and intratumor heterogeneous deficiency differently impact immune responses in diffuse large B-cell lymphomaZijun Y. Xu‐Monette, Ken H. Young, Cancan Luo et al.|OncoImmunology|2024Cited by 2
Real‐life efficacy and safety of vemurafenib plus rituximab in relapsed or refractory hairy‐cell leukemia: A multicenter Italian retrospective study (HCL‐PG03R)Enrico Tiacci, Monia Capponi, Andrea Bernardelli et al.|HemaSphere|2025Cited by 1
The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term results of the Fondazione Italiana Linfomi MCL0208 clinical trialRiccardo Moia, Simone Ferrero, Simone Ragaini et al.|Leukemia|2025Cited by 0